Federated Hermes
KLRA

Federated Hermes’s Kailera Therapeutics KLRA Stock Holding History

Federated Hermes’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.56M Buy
+434,069
New +$9.54M 0.01% 703

Other funds holding KLRA

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Federated Hermes's KLRA Position: Q2 2026 in Review

Federated Hermes opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 434,069 shares worth $9.56M. The stake represents 0.01% of the portfolio and ranks #703 among its holdings.

47 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • Federated Hermes held 434,069 shares of Kailera Therapeutics worth $9.56M as of Q2 2026.
  • Kailera Therapeutics was a new Federated Hermes position in Q2 2026.
  • Kailera Therapeutics made up 0.01% of Federated Hermes's portfolio in Q2 2026, its #703 holding.
  • 47 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.